Know Cancer

forgot password

A Phase 2 and Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma

Phase 2
18 Years
Not Enrolling
Renal Cell Carcinoma

Thank you

Trial Information

A Phase 2 and Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma

This is a Phase 2, open-label, single arm, multi-center, study of orally administered
tivozanib to approximately 100 subjects with advanced renal cell carcinoma (RCC). This study
is designed to evaluate biomarkers in blood and archived tissue samples, and their
correlation with clinical activity and/or treatment-related toxicity in subjects with
advanced RCC, and estimate the percentage of tivozanib-treated subjects who are
progression-free at 6 months, overall response rate (ORR), progression free survival (PFS),
safety and tolerability, and pharmacokinetics (PK). Subjects will be stratified by histology
(clear cell vs. non-clear cell). Enrollment of non-clear cell subjects will be limited to ≤
30% of the entire study population.

Study enrollment is anticipated to complete in approximately 9 months. Treatment duration is
estimated to last approximately 6 months from the subject's first dose of tivozanib with a
follow-up period of 30 days. After 6 months, treatment with tivozanib may continue by
participation in a rollover protocol (AV-951-09-901). Maximum duration of subject
participation in this Phase 2 study is approximately 8 months.

Inclusion Criteria:

1. ≥ 18 year old males or females

2. Subjects with unresectable locally recurrent or metastatic renal cell carcinoma

3. Histologically or cytologically confirmed clear cell renal cell carcinoma (≥ 50%
clear cell) or non-clear cell RCC (all histologies)

4. Subjects must have undergone prior nephrectomy (complete or partial) for excision of
the primary tumor.

5. Measurable disease per RECIST criteria Version 1.1 (see Appendix A)

6. Treatment naïve subjects or subjects who have received no more than one prior
systemic treatment (immunotherapy, including interferon-alfa or interleukin-2 based
therapy, chemotherapy, hormonal therapy or an investigational agent) for metastatic

7. ECOG performance status of 0 or 1, and life expectancy ≥ 3 months

8. If female and of childbearing potential, documentation of negative pregnancy test
prior to enrollment

9. Willingness to provide archival paraffin embedded tumor tissue, if available.

10. Ability to give written informed consent and comply with protocol requirements

Exclusion Criteria:

1. Any prior VEGF-directed therapy including VEGF antibody (eg, bevacizumab), VEGF
receptor tyrosine kinase inhibitor (eg, sunitinib, sorafenib, axitinib, pazopanib,
etc.), VEGF trap (eg, aflibercept), or any other agent or investigational agent
targeting the VEGF pathway.

2. Any prior therapy with an agent targeting the mTOR pathway (eg, temsirolimus,
everolimus, etc)

3. Primary CNS malignancies or CNS metastases; subjects with previously treated brain
metastasis will be allowed if the brain metastasis have been stable without steroid
treatment for at least 3 months following prior treatment (radiotherapy or surgery).

4. Any of the following hematologic abnormalities:

- Hemoglobin < 9.0 g/dL

- Absolute neutrophil count (ANC) < 1500 per mm3

- Platelet count < 100,000 per mm3

- INR >1.5 or PTT >1.5 × ULN

5. Any of the following serum chemistry abnormalities:

- Total bilirubin > 1.5 × ULN (or > 2.5 × ULN for subjects with Gilbert‟s

- AST or ALT > 2.5 × ULN (or > 5 × ULN for subjects with liver metastasis)

- Alkaline phosphatase > 2.5 × ULN (or > 5 × ULN for subjects with liver or
bone metastasis)

- Creatinine > 2.0 × ULN

- Proteinuria > 3+ by urinalysis or urine dipstick

6. Significant cardiovascular disease, including:

- Active clinically symptomatic left ventricular failure.

- Uncontrolled hypertension: Systolic blood pressure > 140 mmHg or diastolic blood
pressure > 90 mmHg on 2 or more antihypertensive medications, documented on 2
consecutive measurements taken at least 24 hours apart.

- Myocardial infarction, severe angina, or unstable angina within 6 months prior
to administration of first dose of study drug.

- History of serious ventricular arrhythmia (ie, ventricular tachycardia or
ventricular fibrillation)

- Cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial
fibrillation that is well controlled with anti-arrhythmic medication)

- Coronary or peripheral artery bypass graft within 6 months of screening

7. Non-healing wound, bone fracture, or skin ulcer.

8. Active peptic ulcer disease, inflammatory bowel disease, ulcerative colitis, or other
gastrointestinal condition with increased risk of perforation; history of abdominal
fistula, gastrointestinal perforation, or intra-abdominal abscess within 4 weeks
prior to administration of first dose of study drug

9. Serious/active infection or infection requiring parenteral antibiotics.

10. Inadequate recovery from any prior surgical procedure or major surgical procedure
within 4 weeks prior to administration of first dose of study drug.

11. Significant thromboembolic or vascular disorders within 6 months prior to
administration of first dose of study drug, including but not limited to:

- Deep vein thrombosis

- Pulmonary embolism

- Cerebrovascular accident (CVA) or transient ischemic attack (TIA)

- Peripheral arterial ischemia > Grade 2 (per CTCAE Version 3.0)

12. Significant bleeding disorders within 6 months prior to administration of first dose
of study drug, including but not limited to.

- Hematemesis, hematochezia, melena or other gastrointestinal bleeding Grade 2
(per CTCAE Version 3.0)

- Hemoptysis or other pulmonary bleeding Grade 2 (per CTCAE Version 3.0)

13. Currently active second primary malignancy, including hematologic malignancies
(leukemia, lymphoma, multiple myeloma, etc.), other than non-melanoma skin cancers,
non-metastatic prostate cancer, in situ cervical cancer, and ductal or lobular
carcinoma in situ of the breast. Subjects are not considered to have a currently
active malignancy if they have completed anti-cancer therapy and have been disease
free for >2 years.

14. Pregnant or lactating females.

15. History of genetic or acquired immune suppression disease such as HIV; subjects on
immune suppressive therapy for organ transplant.

16. Life-threatening illness or organ system dysfunction compromising safety evaluation.

17. Requirement for hemodialysis or peritoneal dialysis.

18. Inability to swallow pills, malabsorption syndrome or gastrointestinal disease that
severely affects the absorption of tivozanib, major resection of the stomach or small
bowel, or gastric bypass procedure.

19. Psychiatric disorder or altered mental status precluding informed consent or
protocol-related testing.

20. Sexually active pre-menopausal female subjects (and female partners of male subjects)
must use adequate contraceptive measures, while on study and for 30 days after the
last dose of study drug. All fertile male and female subjects must agree to use a
highly effective method of contraception (including their partner). Effective birth
control includes:

- IUD plus one barrier method or 2 barrier methods. Effective barrier methods are
male or female condoms, diaphragms, and spermicides (creams or gels that contain
a chemical to kill sperm). (Note: Oral,implantable, or injectable contraceptives

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To evaluate archived tumor tissue samples and their correlation with clinical activity and/or treatment related toxicity.

Outcome Description:

These biomarkers may include but are not limited to: CD68, HIF (hypoxia induced factor)1/HIF2, VEGF A, VEGF-B, VEGF-C, VEGF-D, HGF (hepatocyte growth factor), CAIX, and PLGF (placental growth factor) levels and a biomarker signature based on transcriptional profiles.

Outcome Time Frame:

Archived tumor tissue will be collected from subjects that meet eligibility criteria and will be enrolled on the study.

Safety Issue:



United States: Food and Drug Administration

Study ID:




Start Date:

January 2011

Completion Date:

October 2012

Related Keywords:

  • Renal Cell Carcinoma
  • AV-951
  • Tivozanib
  • Advanced Renal Cell Carcinoma
  • RCC
  • Biomarkers
  • Carcinoma
  • Carcinoma, Renal Cell



Fox Chase Cancer Center Philadelphia, Pennsylvania  19111
Rocky Mountain Cancer Center Denver, Colorado  80218
Medical Oncology, LLC Baton Rouge, Louisiana  70808
Dana Farber Cancer Institute Boston, Massachusetts  02115
Ohio State University Columbus, Ohio  43210
Cancer & Hematology Centers of Western Michigan Grand Rapids, Michigan  49546
The West Clinic Memphis, Tennessee  38120
The Jones Clinic Germantown, Tennessee  38138
David Geffen School of Medicine at UCLA Los Angeles, California  90095
North Mississippi Hematology & Oncology Associates, Ltd. Tupelo, Mississippi  38801
Cancer Center of Kansas Wichita, Kansas  67214
Coastal Bend Cancer Center Corpus Christi, Texas  78404
St. Francis Cancer Research Foundation Beech Grove, Indiana  46107
Texas Oncology-Austin North Austin, Texas  78759
Southern Cancer Center Mobile, Alabama  36608
University of North Carolina, Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina  27599
Comprehensive Cancer Centers of Nevada & US Oncology Research Las Vegas, Nevada  89169
Providence Health and Services Burbank, California  91505
Mary Hitchcock Memorial Hospital, NH Lebanon, New Hampshire  
Texas Oncology-Baylor, Charles A. Sammons Cancer Center Dallas, Texas